logo
Twitter
Discord
Email
logo
Phreesia, Inc.

Phreesia, Inc.

NYSE•PHR
CEO: Mr. Chaim Indig
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2019-07-18
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.
Contact Information
1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, 19803, United States
888-654-7473
www.phreesia.com
Market Cap
$1.23B
P/E (TTM)
-50.6
39.9
Dividend Yield
--
52W High
$32.76
52W Low
$18.55
52W Range
14%
Rank61Top 80.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2024

Financial Dashboard

Q2 2026 Data

Revenue

$117.26M+14.83%
4-Quarter Trend

EPS

$0.01-103.55%
4-Quarter Trend

FCF

$13.07M+257.24%
4-Quarter Trend

2026 Q2 Earnings Highlights

Key Highlights

Revenue Growth Strong 15% Total revenues increased 15% to $117.3M for the three months ended July 31, 2025, driven by client expansion.
Profitability Reverses Losses Achieved $0.7M net income this quarter versus $18.0M net loss prior year; six-month net loss narrowed to $3.3M.
Adjusted EBITDA Expansion Quarterly Adjusted EBITDA reached $22.1M, up $15.6M from 2024; six-month Adjusted EBITDA was $42.9M.
Cash Flow Turns Positive Net cash from operations was $29.7M for six months; Free cash flow was $17.1M, reversing prior period negative flow.

Risk Factors

Intense Industry Competition Highly competitive industry facing EHR/PM systems; failure to compete effectively harms operations and market position.
Managing Rapid Growth Strain Rapid expansion strains operations; failure to manage growth effectively risks efficiency decline and hinders business strategy implementation.
Cybersecurity and Data Risks Collecting sensitive data exposes firm to cyber-attacks, data breaches, and potential legal penalties under privacy laws.
Client Concentration Exposure Historically reliant on a limited number of large clients; sudden loss or unfavorable renegotiation severely impacts operating results.

Outlook

AccessOne Acquisition Planned Definitive agreement signed August 2025 to acquire AccessOne for $160M cash; closing expected Q3/Q4 FY2026.
Liquidity Supports Growth Existing cash ($98.3M) plus Bridge Loan expected sufficient for next 12 months; management may seek further financing.
Focus on EBITDA Goals Management prioritizes maintaining positive net income and growing positive Adjusted EBITDA moving forward.
Scaling Infrastructure Critical Must maintain IT infrastructure and scale capabilities to support anticipated future growth and client implementation needs.

Peer Comparison

Revenue (TTM)

Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Clover Health Investments, Corp.CLOV
$1.77B
+14.8%
Omnicell, Inc.OMCL
$1.18B
+10.7%

Gross Margin (Latest Quarter)

BioCryst Pharmaceuticals, Inc.BCRX
98.6%
+1.4pp
GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp
Phreesia, Inc.PHR
85.2%
+24.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TXG$2.24B-29.8-10.3%8.5%
OMCL$1.83B92.11.6%10.0%
BCRX$1.65B-187.51.9%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.2%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q2 2026

    Period End: Jul 31, 2025|Filed: Sep 5, 2025|
    Revenue: $117.26M+14.8%
    |
    EPS: $0.01-103.5%
    Beat

  • Form 10-Q - Q1 2026

    Period End: Apr 30, 2025|Filed: May 28, 2025|
    Revenue: $115.94M+14.5%
    |
    EPS: $-0.07-81.0%
    Beat

  • Form 10-K - FY 2025

    Period End: Jan 31, 2025|Filed: Mar 13, 2025|
    Revenue: $419.81M+17.8%
    |
    EPS: $-1.02+59.4%
    Miss

  • Form 10-Q - Q3 2025

    Period End: Oct 31, 2024|Filed: Dec 9, 2024|
    Revenue: $106.80M+16.6%
    |
    EPS: $0.65-212.1%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jul 31, 2024|Filed: Sep 5, 2024|
    Revenue: $102.12M+19.0%
    |
    EPS: $-0.31-54.4%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Apr 30, 2024|Filed: May 31, 2024|
    Revenue: $101.22M+20.7%
    |
    EPS: $-0.35-50.0%
    Beat

  • Form 10-K - FY 2024

    Period End: Jan 31, 2024|Filed: Mar 15, 2024|
    Revenue: $356.30M+26.8%
    |
    EPS: $-2.51+25.3%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Oct 31, 2023|Filed: Dec 6, 2023|
    Revenue: $91.62M+25.3%
    |
    EPS: $-0.58-23.7%
    Beat